Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance
The non-coding RNAs comprise a large part of human genome lack of capacity in encoding functional proteins. Among various members of non-coding RNAs, the circular RNAs (circRNAs) have been of importance in the pathogenesis of human diseases, especially cancer. The circRNAs have a unique closed loop structure and due to their stability, they are potential diagnostic and prognostic factors in cancer. The increasing evidences have highlighted the role of circRNAs in the modulation of proliferation and metastasis of cancer cells. On the other hand, metastasis has been responsible for up to 90% of cancer-related deaths in patients, requiring more investigation regarding the underlying mechanisms modulating this mechanism. EMT enhances metastasis and invasion of tumor cells, and can trigger resistance to therapy. The cells demonstrate dynamic changes during EMT including transformation from epithelial phenotype into mesenchymal phenotype and increase in N-cadherin and vimentin levels. The process of EMT is reversible and its reprogramming can disrupt the progression of tumor cells. The aim of current review is to understanding the interaction of circRNAs and EMT in human cancers and such interaction is beyond the regulation of cancer metastasis and can affect the response of tumor cells to chemotherapy and radiotherapy. The onco-suppressor circRNAs inhibit EMT, while the tumor-promoting circRNAs mediate EMT for acceleration of carcinogenesis. Moreover, the EMT-inducing transcription factors can be controlled by circRNAs in different human tumors.
Top-30
Journals
|
2
4
6
8
10
|
|
|
Pathology Research and Practice
10 publications, 14.93%
|
|
|
Cellular Signalling
5 publications, 7.46%
|
|
|
Frontiers in Oncology
5 publications, 7.46%
|
|
|
Frontiers in Immunology
3 publications, 4.48%
|
|
|
Cell Biochemistry and Biophysics
2 publications, 2.99%
|
|
|
Naunyn-Schmiedeberg's Archives of Pharmacology
2 publications, 2.99%
|
|
|
International Immunopharmacology
2 publications, 2.99%
|
|
|
Medical Oncology
2 publications, 2.99%
|
|
|
Arab Journal of Gastroenterology
2 publications, 2.99%
|
|
|
European Journal of Pharmacology
2 publications, 2.99%
|
|
|
Experimental Hematology and Oncology
1 publication, 1.49%
|
|
|
Frontiers in Genetics
1 publication, 1.49%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 1.49%
|
|
|
Inorganic Chemistry Communication
1 publication, 1.49%
|
|
|
PLoS ONE
1 publication, 1.49%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 1.49%
|
|
|
Free Radical Biology and Medicine
1 publication, 1.49%
|
|
|
DNA and Cell Biology
1 publication, 1.49%
|
|
|
Journal of Cell Communication and Signaling
1 publication, 1.49%
|
|
|
AAPS PharmSciTech
1 publication, 1.49%
|
|
|
Epigenomics
1 publication, 1.49%
|
|
|
Frontiers in Pharmacology
1 publication, 1.49%
|
|
|
Cell Biology International
1 publication, 1.49%
|
|
|
Regenerative Therapy
1 publication, 1.49%
|
|
|
International Journal of Biological Macromolecules
1 publication, 1.49%
|
|
|
Journal of Translational Medicine
1 publication, 1.49%
|
|
|
Journal of Molecular Neuroscience
1 publication, 1.49%
|
|
|
Genes and Diseases
1 publication, 1.49%
|
|
|
Oncology Research
1 publication, 1.49%
|
|
|
2
4
6
8
10
|
Publishers
|
5
10
15
20
25
30
35
|
|
|
Elsevier
31 publications, 46.27%
|
|
|
Springer Nature
14 publications, 20.9%
|
|
|
Frontiers Media S.A.
10 publications, 14.93%
|
|
|
Bentham Science Publishers Ltd.
3 publications, 4.48%
|
|
|
Wiley
2 publications, 2.99%
|
|
|
Taylor & Francis
2 publications, 2.99%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 1.49%
|
|
|
Public Library of Science (PLoS)
1 publication, 1.49%
|
|
|
Mary Ann Liebert
1 publication, 1.49%
|
|
|
Cognizant, LLC
1 publication, 1.49%
|
|
|
MDPI
1 publication, 1.49%
|
|
|
5
10
15
20
25
30
35
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.